Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect

Kohji Yamada, Mutsumi Hayashi, Wenlin Du, Kei Ohnuma, Michiie Sakamoto, Chikao Morimoto, Taketo Yamada

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: CD26 is a type II, cell surface glycoprotein known as dipeptidyl peptidase (DPP) IV. Previous studies have revealed CD26 expression in T cell leukemia/lymphoma and malignant mesothelioma, and an inhibitory effect of anti-CD26 monoclonal antibody (mAb) against the growth of CD26+ cancer cells in vitro and in vivo. The function of CD26 in tumor development is unknown and the machinery with which the CD26 mAb induces its anti-tumor effect remains uncharacterized. Results: The localization of CD26 in the nucleus of T cell leukemia/ lymphoma cells and mesothelioma cells was shown by biochemical and immuno-electron microscopic analysis. The DPPIV enzyme activity was revealed in the nuclear fraction of T cell leukemia/lymphoma cells. These expressions of intra-nuclear CD26 were augmented by treatment with the CD26 mAb, 1F7, with anti-tumor effect against the CD26+ T cell leukemia/lymphoma cells. In contrast, the CD26 mAb, 5F8, without anti-tumor effect, did not augment CD26 expressions in the nucleus. Biotin-labeled, cell surface CD26 translocated into the nucleus constantly, and this translocation was enhanced with 1F7 treatment but not with 5F8. Conclusion: These results indicate that the intra-nuclear CD26 which moves from plasma membrane may play certain roles in cell growth of human cancer cells.

Original languageEnglish
Article number17
JournalCancer Cell International
Volume9
DOIs
Publication statusPublished - 2009 Jun 29

Fingerprint

Monoclonal Antibodies
T-Cell Leukemia
T-Cell Lymphoma
Neoplasms
Dipeptidyl Peptidase 4
Mesothelioma
Membrane Glycoproteins
Growth
Biotin
Cell Membrane
Electrons
Enzymes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Genetics

Cite this

Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect. / Yamada, Kohji; Hayashi, Mutsumi; Du, Wenlin; Ohnuma, Kei; Sakamoto, Michiie; Morimoto, Chikao; Yamada, Taketo.

In: Cancer Cell International, Vol. 9, 17, 29.06.2009.

Research output: Contribution to journalArticle

Yamada, Kohji ; Hayashi, Mutsumi ; Du, Wenlin ; Ohnuma, Kei ; Sakamoto, Michiie ; Morimoto, Chikao ; Yamada, Taketo. / Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect. In: Cancer Cell International. 2009 ; Vol. 9.
@article{e40850dc14854812b2ddea672b7505fd,
title = "Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect",
abstract = "Background: CD26 is a type II, cell surface glycoprotein known as dipeptidyl peptidase (DPP) IV. Previous studies have revealed CD26 expression in T cell leukemia/lymphoma and malignant mesothelioma, and an inhibitory effect of anti-CD26 monoclonal antibody (mAb) against the growth of CD26+ cancer cells in vitro and in vivo. The function of CD26 in tumor development is unknown and the machinery with which the CD26 mAb induces its anti-tumor effect remains uncharacterized. Results: The localization of CD26 in the nucleus of T cell leukemia/ lymphoma cells and mesothelioma cells was shown by biochemical and immuno-electron microscopic analysis. The DPPIV enzyme activity was revealed in the nuclear fraction of T cell leukemia/lymphoma cells. These expressions of intra-nuclear CD26 were augmented by treatment with the CD26 mAb, 1F7, with anti-tumor effect against the CD26+ T cell leukemia/lymphoma cells. In contrast, the CD26 mAb, 5F8, without anti-tumor effect, did not augment CD26 expressions in the nucleus. Biotin-labeled, cell surface CD26 translocated into the nucleus constantly, and this translocation was enhanced with 1F7 treatment but not with 5F8. Conclusion: These results indicate that the intra-nuclear CD26 which moves from plasma membrane may play certain roles in cell growth of human cancer cells.",
author = "Kohji Yamada and Mutsumi Hayashi and Wenlin Du and Kei Ohnuma and Michiie Sakamoto and Chikao Morimoto and Taketo Yamada",
year = "2009",
month = "6",
day = "29",
doi = "10.1186/1475-2867-9-17",
language = "English",
volume = "9",
journal = "Cancer Cell International",
issn = "1475-2867",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect

AU - Yamada, Kohji

AU - Hayashi, Mutsumi

AU - Du, Wenlin

AU - Ohnuma, Kei

AU - Sakamoto, Michiie

AU - Morimoto, Chikao

AU - Yamada, Taketo

PY - 2009/6/29

Y1 - 2009/6/29

N2 - Background: CD26 is a type II, cell surface glycoprotein known as dipeptidyl peptidase (DPP) IV. Previous studies have revealed CD26 expression in T cell leukemia/lymphoma and malignant mesothelioma, and an inhibitory effect of anti-CD26 monoclonal antibody (mAb) against the growth of CD26+ cancer cells in vitro and in vivo. The function of CD26 in tumor development is unknown and the machinery with which the CD26 mAb induces its anti-tumor effect remains uncharacterized. Results: The localization of CD26 in the nucleus of T cell leukemia/ lymphoma cells and mesothelioma cells was shown by biochemical and immuno-electron microscopic analysis. The DPPIV enzyme activity was revealed in the nuclear fraction of T cell leukemia/lymphoma cells. These expressions of intra-nuclear CD26 were augmented by treatment with the CD26 mAb, 1F7, with anti-tumor effect against the CD26+ T cell leukemia/lymphoma cells. In contrast, the CD26 mAb, 5F8, without anti-tumor effect, did not augment CD26 expressions in the nucleus. Biotin-labeled, cell surface CD26 translocated into the nucleus constantly, and this translocation was enhanced with 1F7 treatment but not with 5F8. Conclusion: These results indicate that the intra-nuclear CD26 which moves from plasma membrane may play certain roles in cell growth of human cancer cells.

AB - Background: CD26 is a type II, cell surface glycoprotein known as dipeptidyl peptidase (DPP) IV. Previous studies have revealed CD26 expression in T cell leukemia/lymphoma and malignant mesothelioma, and an inhibitory effect of anti-CD26 monoclonal antibody (mAb) against the growth of CD26+ cancer cells in vitro and in vivo. The function of CD26 in tumor development is unknown and the machinery with which the CD26 mAb induces its anti-tumor effect remains uncharacterized. Results: The localization of CD26 in the nucleus of T cell leukemia/ lymphoma cells and mesothelioma cells was shown by biochemical and immuno-electron microscopic analysis. The DPPIV enzyme activity was revealed in the nuclear fraction of T cell leukemia/lymphoma cells. These expressions of intra-nuclear CD26 were augmented by treatment with the CD26 mAb, 1F7, with anti-tumor effect against the CD26+ T cell leukemia/lymphoma cells. In contrast, the CD26 mAb, 5F8, without anti-tumor effect, did not augment CD26 expressions in the nucleus. Biotin-labeled, cell surface CD26 translocated into the nucleus constantly, and this translocation was enhanced with 1F7 treatment but not with 5F8. Conclusion: These results indicate that the intra-nuclear CD26 which moves from plasma membrane may play certain roles in cell growth of human cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=67651024959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651024959&partnerID=8YFLogxK

U2 - 10.1186/1475-2867-9-17

DO - 10.1186/1475-2867-9-17

M3 - Article

C2 - 19555512

AN - SCOPUS:67651024959

VL - 9

JO - Cancer Cell International

JF - Cancer Cell International

SN - 1475-2867

M1 - 17

ER -